China603229.CG▼
Aoxiang Pharmaceutical's first-half net profit attributable to parent was 120 million yuan, down 29.2% year-on-year
Aoxiang Pharmaceutical released its 2026 interim report. Net profit attributable to the parent in the first half was 120 million yuan, down 29.2% year-on-year. Operating revenue was 468 million yuan, down 3.0% year-on-year. Net profit attributable to the parent after deducting non-recurring items was 80.5 million yuan, down 46.7% year-on-year. Net operating cash flow was negative 42.36 million yuan, down 193.3% year-on-year. In the second quarter, operating revenue was 159 million yuan, down 9.3% year-on-year. Net profit attributable to the parent was 23.18 million yuan, down 53.8% year-on-year. Net profit attributable to the parent after deducting non-recurring items was a loss of 11.88 million yuan. The company said the decline in net operating cash flow was mainly due to reduced collection of payments for goods, exchange losses of 37.68 million yuan caused by fluctuations in the US dollar exchange rate, and intensified industry competition squeezing profit margins. During the reporting period, research and development investment reached 57.87 million yuan, accounting for 12.38% of operating revenue.